
    
      C6463-202 will evaluate the safety, tolerability, PK, and PD of CY6463 vs placebo in
      participants with ADv. Participants will be randomized to receive approximately 87 sequential
      days (~12 weeks) of study drug (CY6463 or placebo) once daily (QD), and will complete 7
      scheduled site visits over the course of the study, from Screening through Follow up.
    
  